Cost-effectiveness analysis of quadrivalent influenza vaccine versus trivalent influenza vaccine for elderly in Hong Kong
Open Access
- 25 November 2014
- journal article
- research article
- Published by Springer Nature in BMC Infectious Diseases
- Vol. 14 (1) , 618
Abstract
Cost and quality-adjusted life-years (QALYs) gained by quadrivalent influenza vaccine (QIV) versus trivalent influenza vaccine (TIV) in Hong Kong elderly were estimated over 9 seasons. TIV-unmatched influenza B infection rates with QIV versus TIV were estimated by an epidemiology model. Model parameters included percentages of influenza B lineages in circulation, influenza B-associated hospital admission, age-specific population, vaccine coverage and effectiveness. Incremental cost per QALY gained (ICER) by QIV versus TIV were estimated from Hong Kong’s societal perspective. Mean reduction in influenza B infection rate was 191.3 (95%CI 45.1-337.5) per 100,000 population aged ≥65 years. Highest cost savings and QALYs gained by QIV occurred in 2007 with high percentage of TIV-unmatched strain (92.9%) for age groups 65–79 years (USD266,473 and 22.8 QALYs) and ≥80 years (USD483,461 and 27.3 QALYs). ICERs of QIV were below willingness-to-pay for age group 65–79 years in 6, 5 and 3 years when QIV cost + USD1 + USD2 and + USD5 more than TIV, respectively. For age group ≥80 years, ICERs of QIV were below willingness-to-pay in 7 and 5 years when QIV cost + USD1 and + USD5, correspondingly. Acceptance of QIV to be cost-effective in Hong Kong elderly was subject to QIV unit cost and percentage of circulating TIV-unmatched influenza B lineages.Keywords
This publication has 27 references indexed in Scilit:
- Influenza B Lineage Circulation and Hospitalization Rates in a Subtropical City, Hong Kong, 2000–2010Clinical Infectious Diseases, 2012
- Prevention of Symptomatic Seasonal Influenza in 2005–2006 by Inactivated and Live Attenuated VaccinesThe Journal of Infectious Diseases, 2008
- Interim within-season estimate of the effectiveness of trivalent inactivated influenza vaccine--Marshfield, Wisconsin, 2007-08 influenza season.2008
- Seasonal influenza in the United States, France, and Australia: transmission and prospects for controlEpidemiology and Infection, 2007
- Post-Exposure Influenza Prophylaxis with OseltamivirPharmacoEconomics, 2006
- Management of influenza symptoms in healthy adultsJournal of General Internal Medicine, 2003
- Cost-effectiveness of newer treatment strategies for influenzaThe American Journal of Medicine, 2002
- One Thousand Health-Related Quality-of-Life EstimatesMedical Care, 2000
- Toward Consistency in Cost-Utility AnalysesMedical Care, 1998
- The utility of different health states as perceived by the general publicJournal of Chronic Diseases, 1978